 |
인쇄하기
취소
|
Korea's homegrown new drug gets approval in China
Ilyang Pharm has received marketing approval for ilaprazole, a new investigational proton pump inhibitor, from the Chinese drug regulatory agency (SFDA).
The ulcerant market in China has shown over 30-percent growth every year. The market for proton pump inhibitors is estimated at 700 billion, which has been predominated
Livzon Inc. said that ilaprazole is expected to grab about 30 perce...
The ulcerant market in China has shown over 30-percent growth every year. The market for proton pump inhibitors is estimated at 700 billion, which has been predominated
Livzon Inc. said that ilaprazole is expected to grab about 30 perce...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.